NoCanTher - Nanomedicine upscaling for early clinical phases of multimodal cancer therapy

NoCanTher is an european research and innovation project funded by the Horizon 2020 programme and under Industrial Leadership frame. Its goal is to translate the nanoformulations against pancreatic cancer to an early clinical development.

Consortium: 11 partners from EU countries.

Timeframe: 60 months.

Coordinator: IMDEA Nanociencia.


Vision and mission

Pancreatic ductal adenocarcinoma is an orphan disease with a very bad prognosis, even when diagnosed early. The survival rate after 5 years (< 5%) has not changed over the last 30 years, despite tremendous efforts at the preclinical and clinical stage. There is an urgent need to develop effective treatments for this disease, and since the standard approaches have not afforded any significant improvement, the use of novel therapies might be the solution for this particular case. In this regard, the use of nanotechnology-based approaches have been applied in the last years for the detection and treatment of multiple diseases. In this context, the consortium NoCanTher aims to scale-up under GMP (Good Manufacturing Practices) conditions and evaluate a nanoformulation based on magnetic nanoparticles for a combined therapy against this disease.